Cyramza Use In Pregnancy & Lactation

Women of childbearing potential/Contraception in females: Women of childbearing potential should be advised to avoid becoming pregnant while on Ramucirumab (Cyramza) and should be informed of the potential hazard to the pregnancy and fetus. Women of childbearing potential should use effective contraception during and up to 3 months after the last dose of ramucirumab treatment.
Pregnancy: There are no data from the use of ramucirumab in pregnant women. Animal studies are insufficient with respect to reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions). As angiogenesis is critical to maintenance of pregnancy and to fetal development, the inhibition of angiogenesis following ramucirumab administration may result in adverse effects on pregnancy, including the fetus. Ramucirumab (Cyramza) should only be used if the potential benefit to the mother justifies the potential risk during pregnancy. If the patient becomes pregnant while being treated with ramucirumab, she should be informed of the potential risk to the maintenance of pregnancy and the risk to the fetus. Ramucirumab (Cyramza) is not recommended during pregnancy and in women of childbearing potential not using contraception.
Breastfeeding: It is unknown whether ramucirumab is excreted in human milk. Excretion in milk and oral absorption is expected to be low. As a risk to breastfed newborns/infants cannot be excluded, breastfeeding should be discontinued during treatment with Ramucirumab (Cyramza) and for at least 3 months after the last dose.
Fertility: There are no data on the effect of ramucirumab on human fertility. Female fertility is likely to be compromised during treatment with ramucirumab based on studies in animals (see Pharmacology: Toxicology: Preclinical safety data under Actions).